Key result
Empagliflozin plus losartan reduces SBP 15 mmHg versus placebo in T2D, beating either drug alone.
Why the study?
To evaluate the blood pressure-lowering effects and potential underlying mechanisms of empagliflozin, losartan, and their combination in people with type 2 diabetes.
Does the combination of empagliflozin and losartan reduce blood pressure more than either drug alone in people with type 2 diabetes?
RCT
double-blind
crossover
Does the combination of empagliflozin and losartan reduce blood pressure more than either drug alone in people with type 2 diabetes?
In patients with type 2 diabetes, combining empagliflozin and losartan yields greater blood pressure reductions than either monotherapy through partially distinct mechanisms.
Answers are grounded in this paper and cite their sources.
Supports combining empagliflozin and losartan for greater SBP reduction in T2D; confirms additive effects beyond monotherapy.
AIM: To study the effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin, the angiotensin receptor blocker (ARB) losartan, and their combination on blood pressure, while studying the mechanisms potentially involved. METHODS: ) received a 1-week treatment with empagliflozin 10 mg once daily, losartan 50 mg once daily, their combination, and placebo, in a randomized double-blind crossover design, with 4-week washout periods in between. Blood pressure, arterial stiffness, autonomic nervous system activity and plasma volume, extracellular fluid and serum albumin were assessed. RESULTS: Versus placebo (139 mmHg), empagliflozin reduced systolic blood pressure (SBP) by 8 mmHg (P = .001), losartan by 12 mmHg (P = .001) and empagliflozin + losartan by 15 mmHg (P < .001). Combination therapy had a larger SBP-lowering effect versus empagliflozin monotherapy (-7 [95% CI -12; -2] mmHg) and numerically larger effects versus losartan monotherapy (-3 [-8; 2] mmHg). Empagliflozin reduced sympathetic nervous system (SNS) activity, arterial stiffness and extracellular fluid, while increasing serum albumin. Losartan reduced SNS activity and arterial stiffness. Combination therapy induced volume contraction variables, together with a reduction in SNS activity and arterial stiffness. CONCLUSION: In people with T2D, SGLT2 inhibition in combination with an ARB had a larger blood pressure-lowering effect versus placebo than either of the drugs alone. Our data further suggest that the mechanisms underlying these blood pressure reductions at least partially differ between these agents.
No takes yet. Share an insight, caveat, or question.
Scholtes et al. (2022) conducted an RCT in type 2 diabetes. empagliflozin, losartan, and their combination vs. placebo was evaluated on systolic blood pressure (SBP) (-15 mmHg, p=<.001). In people with type 2 diabetes, the combination of empagliflozin and losartan reduced systolic blood pressure by 15 mmHg versus placebo, a larger effect than either drug alone.
Synapse has enriched 10 related papers. Consider them for comparative context: